Publication | Open Access

Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

Second-line TreatmentSurgical OncologyEsophageal CancerGastrointestinal OncologyMedicineGastroenterologyPathologyAdvanced GastricPhase 2OncologyRadiation OncologyCancer Research